Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been given an average recommendation of “Buy” by the six analysts that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have updated their coverage on […]
More Stories
Byrna Technologies Inc. (NASDAQ:BYRN) Short Interest Up 10.1% in October
Byrna Technologies Inc. (NASDAQ:BYRN – Get Free Report) was the target of a large increase in short interest during the...
Brixmor Property Group (NYSE:BRX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS
Brixmor Property Group (NYSE:BRX – Get Free Report) issued its quarterly earnings results on Monday. The real estate investment trust...
CBAK Energy Technology, Inc. (NASDAQ:CBAT) Short Interest Update
CBAK Energy Technology, Inc. (NASDAQ:CBAT – Get Free Report) saw a large increase in short interest in October. As of...
Astar (ASTR) Hits Self Reported Market Capitalization of $416.87 Million
Astar (ASTR) traded 2% higher against the U.S. dollar during the 24 hour period ending at 21:00 PM Eastern on...
Boston Properties (NYSE:BXP) Releases FY 2024 Earnings Guidance
Boston Properties (NYSE:BXP – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The...
Ripio Credit Network Price Tops $0.0017 on Major Exchanges (RCN)
Ripio Credit Network (RCN) traded 2.6% higher against the US dollar during the 24-hour period ending at 21:00 PM E.T....